
    
      The study consists of a dose escalation and expansion phase (Phase Ib) to determine the
      recommended Phase 2 dose (RP2D) for AK104 in combination with oxaliplatin and capecitabine,
      and a dose confirmation phase (Phase II) which will further characterize the treatment of
      AK104 in combination at the RP2D.
    
  